<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825161</url>
  </required_header>
  <id_info>
    <org_study_id>SPN-12-002</org_study_id>
    <nct_id>NCT01825161</nct_id>
  </id_info>
  <brief_title>The Epidemiology, Process and Outcomes of Spine Oncology (EPOSO)</brief_title>
  <acronym>EPOSO</acronym>
  <official_title>The Epidemiology, Process and Outcomes of Spine Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AOSpine International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthopaedic Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AOSpine International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to utilize a comprehensive, prospective clinical database
      to collect patient, diagnostic and treatment variables along with disease specific and
      generic health related quality of life (HRQOL) data on consecutively treated patients with
      metastatic spine tumors. The objectives are to determine the validity and reliability of the
      Spine Cancer Outcomes Questionnaire (SCOQ) for use in the assessment of spine tumor outcomes,
      to determine if the Spine Instability Neoplastic Score (SINS) Classification is a valid tool
      for predicting the stability of spine in metastatic spine disease, and to determine the
      efficacy of surgery versus radiotherapy for the treatment of impending instability secondary
      to metastatic disease of the spine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Spine Cancer Outcomes Questionnaire (SCOQ)</measure>
    <time_frame>0, 6, 12, 26, 52 and 104 weeks</time_frame>
    <description>This is a new questionnaire, also referred to as the Spine Oncology Self-Assessment, developed by members of the SOSG. It is made up of 5 domains: physical function, neural function, pain, mental health and social function. It was developed as a comparison to the SF-36 for patients with spine tumors. The reliability and validity of this questionnaire will be compared with the SF-36v2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Numeric Rating Scale (NRS)</measure>
    <time_frame>0, 6, 12, 26, 52 and 104 weeks</time_frame>
    <description>The Pain NRS is an 11-point horizontal scale where the end points are the extremes of no pain (0) and pain as bad as it could be, or worst pain (10). It measures subjective intensity of pain and the patient rates his/her overall or average daily pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQoL 5D (EQ-5D)</measure>
    <time_frame>0, 6, 12, 26, 52 and 104 weeks</time_frame>
    <description>The EuroQOL group developed a standardized instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it contains 5 questions and provides a simple descriptive profile and a single index value for health status. EQ-5D is designed for self-completion by respondents and is ideally suited for use in mailed surveys, in clinics and face-to-face interviews. It is cognitively simple, taking only a few minutes to complete. Instructions to respondents are included in the questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form 36 version 2 (SF-36 v2)</measure>
    <time_frame>0, 6, 12, 26, 52 and 104 weeks</time_frame>
    <description>The SF-36 v2 (Medical Outcomes Trust, Boston, MA) is a multipurpose, short-form health survey with 36 questions available in several languages. It yields an eight-scale profile of scores: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. In addition, two composite scores are constructed using factorial modeling, one for physical health (Physical Composite Score - PCS) and one for mental health (Mental Composite Score - MCS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)</measure>
    <time_frame>0, 6, 12, 26, 52 and 104 weeks</time_frame>
    <description>ISNCSCI is a standardized examination to determine neurologic function and has been a standard clinical assessment for patients with neurological deficit. The modified ISNCSCI used in this study will assess the Motor Score and the ASIA Impairment Scale V 1.3 only.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Secondary Malignant Neoplasm of Vertebral Column</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic spine disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Age between 18 and 75 years

          -  Able to read and write English at an elementary level

          -  Diagnosis of metastatic tumor of the spine

        Exclusion Criteria:

          -  The primary cancer site is central nervous system or spine

          -  History of substance abuse (recreational drugs, alcohol) within 12 months prior to
             screening

          -  Is a prisoner

          -  A disease or condition that would, in opinion of the investigator, preclude accurate
             evaluation (e.g. significant psychiatric disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles G Fisher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vancouver General Hospital and the University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Voegtli, MSc</last_name>
    <email>daniela.voegtli@aofoundation.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niccole Germscheid, MSc</last_name>
    <email>ngermscheid@aospine.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Arnold, MD</last_name>
      <phone>913-588-7587</phone>
      <email>parnold@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linda Ijianas</last_name>
      <email>ljianas@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Sciubba, MD</last_name>
      <email>dsciubb1@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Zach Pennington</last_name>
      <email>zpennin1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Sciubba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Clarke, MD</last_name>
      <email>Clarke.Michelle@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Twaites</last_name>
      <email>Twaites.Sandra@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michelle Clarke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Schuster, MD</last_name>
      <phone>215-615-4587</phone>
      <email>schustej@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Francis Quattrone, MD</last_name>
      <email>Francis.Quattrone@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Rhines, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Michelle Kennedy</last_name>
      <email>mrkennedy@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Laurence Rhines, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Fisher, MD</last_name>
      <phone>(604) 875-4746</phone>
      <email>Charles.Fisher@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Charles Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arjun Sahgal, MD</last_name>
      <email>Arjun.Sahgal@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mikki Campbell</last_name>
      <email>mikki.campbell@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Arjun Sahgal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toronto Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fehlings, MD</last_name>
      <phone>(416) 603-5627</phone>
      <email>Michael.Fehlings@uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Yuriy Petrenko, MD</last_name>
      <phone>(416) 603-5285</phone>
      <email>yuriy.petrenko@uhn.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Fehlings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Weber, MD</last_name>
      <email>michael.weber@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Francis Colagiacomo</last_name>
      <email>francis.colagiacomo@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Weber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center for Spinal Disorders</name>
      <address>
        <city>Budapest</city>
        <zip>1126</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Varga, MD</last_name>
      <phone>+36-1-489-5211</phone>
      <email>vpp@bhc.hu</email>
    </contact>
    <contact_backup>
      <last_name>Aron Lazary, MD</last_name>
      <email>lazary.aron@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aospine.org</url>
    <description>AOSpine</description>
  </link>
  <link>
    <url>http://www.oref.org</url>
    <description>Orthopedic Research Foundation</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

